Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • GBMA Executive and Board
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Historical Event Reporting
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
        • 2021
        • 2022
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • New 5-year Strategic Agreement
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • International Generic and Biosimilar Medicines Association (IGBA)
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2023
    • News 2022
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Biosimilars / GBMA Position on Biosimilars / Key Figures on Biosimilars

Key Figures on Biosimilars

A biosimilar medicine is a highly similar version of an original brand of medicine. Introduction into the market provides competition and can trigger price reductions to the PBS through a process called Price Disclosure.

This means the Government can re-invest savings into other new treatments and health care services – like childcare, eldercare, mental health services,  research and more.

Contact the GBMA to learn more about how biosimilar medicines can contribute to the future sustainability of the Australian healthcare system.

View PDF file

IGBA’s Annual Global Biosimilars Week Focuses on Oncology Care

November 14, 2023

Tuesday, November 14, 2023 Geneva, Switzerland In the week … More...

Neo Health joins GBMA under new membership tier

September 28, 2023

Thursday, September 28, 2023 Canberra, … More...

GBMA welcomes Teva Pharma to its growing membership base

July 24, 2023

Tuesday July 25, 2023 Canberra, … More…

© 2023 Generic and Biosimilar Medicines Association Pty Ltd | Privacy Policy | Contact Us